Get the latest news on Bone Biologics stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on BBLGW performance

Latest Bone Biologics Stock News | NASDAQ:BBLGW | Benzinga

Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.

Bone Biologics Corp

Press Releases

First Two Patients Treated in Pilot Clinical Study with Bone Biologics' NB1 Bone Graft Device in Spine Fusion

Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

BBLG

BBLGW

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Bone Biologics

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Comments

Bone Biologics Stock News

News

Latest Bone Biologics Stock News | NASDAQ:BBLGW | Benzinga

People Also Watch

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga